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Abstract The 8-oxoguanine DNA glycosylase (OGG1) gene
has been considered to be associated with cancer
susceptibility. TheOGG1 Ser326Cys polymorphism has been
reported to be associated with pancreatic cancer (PC), but the
published studies have yielded inconsistent results. For better
understanding of the effect of OGG1 Ser326Cys
polymorphism on PC susceptibility, a meta-analysis was
performed. All eligible studies were identified through a
search of PubMed, Excerpta Medica Database (Embase),
Elsevier Science Direct, and Chinese Biomedical Literature
Database before May 2013. The association between the
OGG1 Ser326Cys polymorphism and PC risk was conducted
by odds ratios (ORs) and 95 % confidence intervals (CIs). A
total of five case–control studies with 1,690 cases and 3,650
controls were eventually collected. Overall, we found that
OGG1 Ser326Cys polymorphism was not associated with
PC susceptibility (Cys/Cys vs. Ser/Ser: OR=0.95, 95 % CI=
0.80–1.14; Cys/Cys vs. Ser/Ser+Ser/Cys: OR=0.95, 95 %
CI=0.78–1.14; Cys/Cys+Ser/Cys vs. Ser/Ser (OR=1.00,
95 % CI=0.89–1.12)). In the subgroup analysis based on
ethnicity, source of control, sample size, and genotyping
method, no significant association was found in any genetic
models. This meta-analysis suggests that the OGG1
Ser326Cys polymorphism may not associated with PC
susceptibility. Considering the limited sample size and
ethnicity included in the meta-analysis, further larger scaled
and well-designed studies are needed to confirm our results.
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Introduction
Pancreatic cancer (PC) is one of the most fatal malignant
tumors among human; although infrequent, it takes up 3 %
of all reported cases of cancer and it is the fourth most
common cause of cancer-related deaths in the USA and the
eighth worldwide [1–3].What was worse, the prognosis of PC
is very poor; the 5-year survival rate is less than 5% even with
the surgical and chemotherapy intervention. There were 44,
000 new cases diagnosed and 37,000 deaths from PC in 2012
[4–6]. The situation has not significantly changed over the
past several decades [7]. It is extremely important for us to
find more effective methods to treat PC. So, having a good
knowledge of the molecular basis of PC is necessary [8, 9]. A
large number of studies have been carried out to explore
potential risk factors of PC. Several factors have been
considered as risk factors, such as diabetes [9], heavy alcohol
consumption [10], smoking [11], and sucrose intake [12].
However, not all people exposed to those risk factors develop
PC, suggesting a genetic contribution to the development of
PC [13, 14].
The 8-oxoguanine DNA glycosylase (OGG1 ) gene,
located on chromosome 3p26, is one of the component of
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BER pathway, plays a key role in repairing damaged DNA. It
performs the initial step of recognizing the 8-hydroxyguanine
damage which is highly mutagenic and a major form of
oxidative DNA damage [15, 16]. TheOGG1 gene has at least
20 validated sequence variants, and one of the most studied
functional polymorphism is Ser326Cys (exon 7 of the OGG1
gene, rs1052133), which with an acid substitution of serine
(Ser) with cysteine (Cys) at codon 326, resulting from a C toG
transversion at 1245 position, has been reported to affect the
OGG1 function and to be associated with cancer
susceptibility [17–21]. It is reported that the 326Cys allele
had reduced DNA repair activity and was related with cancer
risk [20, 21]. Up to now, many reports have evaluated the
relationship between the OGG1 Ser326Cys polymorphism
and PC risk. However, the results from these studies were
inconsistent [22–26]. In order to assess the association
between the OGG1 Ser326Cys polymorphism and PC risk
accurately, we carried out a meta-analysis.
Materials and methods
Literature search
We searched the relevant articles through the search engines
such as PubMed, Excerpta Medica Database (Embase),
Elsevier Science Direct, and Chinese Biomedical Literature
Database using the search terms: “OGG1 ,OGH1 , orOGG1”,
“variant or variation or polymorphism”, and “pancreatic
cancer” (last search was updated on 30 May 2013) without
language restrict.
Inclusion and exclusion criteria
Studies were selected if they satisfied the following criteria:
(1) estimating the association of OGG1 Ser326Cys
polymorphisms with PC risk, (2) case–control studies, (3)
offering enough information for estimating the odds ratios
(ORs) with the corresponding 95 % confidence intervals
(CIs). The exclusion criteria were: (1) not case–control studies
that evaluated the association between OGG1 polymorphism
and PC risk; (2) case reports, letters, and reviews; and (3)
controls were not consistent in HWE.
Data extraction
All the data were extracted by two investigators (YYand XC)
independently and the result was reviewed by a third
investigator (HL). From each study, the following information
were collected: first author, year of publication, country and
ethnicity of the study population, the number of cases and
controls, genotyping methods and genotype distribution of
cases and controls, and source of control.
Statistical analysis
To test whether the population of control conformed to
Hardy–Weinberg equilibrium, a chi-square test was applied.
The homogeneity among the studies was verified by Chi
square-based Q test [27] if there is a significant Q statistic
(P <0.10) that indicated heterogeneity across studies, the
pooled OR estimate of all studies would be calculated by the
fixed-effects model (the Mantel–Haenszel method) [28];
otherwise, a random effects model (the DerSimonian and
Laird method) would be used [29]. The strength of the
association between OGG1 Ser326Cys polymorphism and
PC risk was measured by OR with 95 % CI. The statistical
significance of the summary OR was determined with the Z
test. The publication bias was tested by funnel plot and
Egger’s linear regression test [30, 31]. Sensitivity was analysis
by sequential omission of individual study one a time or by
omitting studies without high quality was performed to assess
the stability of the results [32]. All statistical tests for this
meta-analysis were performed with STATA version 9.0
(Stata Corporation, College Station, TX, USA).
Results
Studies characteristics
The general characteristics of eligible studies were listed in
Table 1. After selecting based on the inclusion and exclusion
criteria listed above, a total of five eligible studies with 1,690
cases and 3,650 controls were included in our meta-analysis
[22–26]. The population of controls in each study was
consistent with HWE (P >0.05).
Table 1 Main characteristics
of studies included in the
meta-analysis
HWE Hardy–Weinberg
equilibrium, HB hospital based,
PB population based






Nakao 2012 Japan Asian Taq Man HB 185/1,465 Yes
Li 2009 USA Caucasians Taq Man HB 722/773 Yes
Duell 2008 USA Caucasians Masscode PB 126/330 Yes
McWilliams 2008 USA Caucasians SNPstream PB 469/599 Yes
Zhang 2011 USA Caucasians Taq Man PB 188/483 Yes
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Table 2 Meta-analysis of OGG1 Ser326Cys polymorphism with the PC risk
Study group N Cys vs Ser Cys/Cys vs Ser/Ser Cys/Cys vs Ser/Ser+Ser/Cys Cys/Cys+Ser/Cys vs Ser/Ser
OR (95 % CI) I2 OR (95 % CI) I2 OR (95 % CI) I2 OR (95 % CI) I2
Overall 5 0.98 (0.95–1.05) 25.4 0.95 (0.80–1.14) 0.0 0.95 (0.78–1.14) 0.0 1.00 (0.89–1.12) 66.3
Ethnicity
Caucasians 4 0.98 (0.90–1.17) 43.9 0.96 (0.74–1.23) 0.0 0.94 (0.73–1.21) 0.0 1.00 (0.85–1.18) 73.7
Asian 1 0.98 (0.87–1.09) - 0.95 (0.75–1.21) – 0.96 (0.73–1.26) – 0.98 (0.89–1.08) –
Control population
Population-based 3 0.93 (0.79–1.11) 54.1 0.95 (0.73–1.33) 28.7 0.98 (0.72–1.34) 0.0 0.96 (0.74–1.26) 81.9
Hospital-based 2 1.01 (0.92–1.10) 0.0 0.94 (0.76–1.16) 0.0 0.93 (0.73–1.17) 0.0 1.03 (0.95–1.11) 3.0
Sample size
>500 subjects 4 1.00 (0.93–1.08) 0.0 0.97 (0.81–1.16) 0.0 0.95 (0.78–1.15) 0.0 1.04 (0.97–1.11) 38.3
≤500 subjects 1 0.73 (0.55–0.97) – 0.80 (0.49–1.32) - 0.97 (0.48–1.95) – 0.69 (0.52–0.92) –
Genotyping method
TaqMan 3 1.02 (0.94–1.10) 0.0 1.01 (0.83–1.22) 0.0 0.98 (0.79–1.21) 0.0 1.08 (0.95–1.19) 56.1
Non-TaqMan 2 0.86 (0.66–1.12) 64.4 0.80 (0.54–1.20) 0.0 0.85 (0.56–1.28) 0.0 0.84 (0.60–1.20) 79.6
N number of studies, P the P value used to test the heterogeneity, CI confidence interval
Fig. 1 Forest plots showed that OGG1 Ser326Cys polymorphism was
not associated with PC susceptibility under all genetic models. a Allele
contrast: Cys vs Ser; b homozygote model, Cys/Cys vs Ser/Ser; c
recessive model, Cys/Cys vs Ser/Ser+Ser/Cys; d dominant model, Cys/
Cys+Ser/Cys vs Ser/Ser
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Meta-analysis
As shown in Table 2, there is no significant association
between the OGG1 Ser326Cys and PC risk was found in
any of the genetic models. The results are as follow: Cys vs.
Ser (OR=0.98, 95 % CI=0.95–1.05; Fig. 1a); Cys/Cys vs.
Ser/Ser: OR=0.95, 95%CI=0.80–1.14 (Fig. 1b); Cys/Cys vs.
Ser/Ser+Ser/Cys: OR=0.95, 95 % CI=0.78–1.14 (Fig. 1c);
Cys/Cys+Ser/Cys vs. Ser/Ser (OR=1.00, 95 % CI=0.89–
1.12; Fig. 1d). Further subgroup analysis by ethnicity, source
of controls, sample size, and genotypingmethod all yielded no
statistically significant estimates (Table 2).
Test of heterogeneity
In the current study, significant heterogeneity was only found
in dominant model (Cys/Cys+Ser/Cys vs Ser/Ser: P =0.018,
I2=66.3 %). Then, we assessed the source of heterogeneity by
ethnicity (Caucasians or Asian), source of control (population-
or hospital-based), sample size (>500 subjects or ≤500
subjects), and genotyping method (TaqMan or non-TaqMan).
As a result, the source of control (χ2=12.23; df=1; I2=91.8%)
and sample size (χ2=2.10; df =1; I2=52.3 %) were found
contribute substantial heterogeneity.
Sensitivity analyses and publication bias
Sensitivity analysis was carried out to evaluate the influence
of each individual study on the pooled OR. The results
indicated that no individual study significantly impact on the
overall results. The publication bias was assessed by Egger’s
test and funnel plot. No publication bias was detected for
OGG1 Ser326Cys (the Egger’s test result as follow: Cys vs.
Ser: P =0.256, Cys/Cys vs. Ser/Ser: P =0.877, Cys/Cys vs.
Ser/Ser+Ser/Cys: P =0.982, Cys/Cys+Ser/Cys vs. Ser/Ser=
0.643). The shape of the funnel plot did not indicate any
evidence of obvious asymmetry too (Fig. 2).
Fig. 2 Funnel plots did not indicate any evidence of obvious asymmetry under all genetic models. a Allele contrast, Cys vs Ser; b homozygote model:
Cys/Cys vs Ser/Ser; c recessive model: Cys/Cys vs Ser/Ser+Ser/Cys; d dominant model: Cys/Cys+Ser/Cys vs Ser/Ser
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Discussion
In recent years, a number of studies have carried out to explore
the OGG1 Ser326Cys polymorphism with cancers risk
including lung cancer, breast cancer, colorectal cancer, and
PC. Unfortunately, previous findings of OGG1 Ser326Cys
polymorphism on cancer susceptibility were controversial or
ambiguous. Therefore, some meta-analyses were performed
to solve the phenomenon. Zhang et al. reported that theOGG1
Ser326Cys polymorphism is not associatedwith CRC risk and
Wang et al. concluded that the OGG1 Ser326Cys
polymorphism might not be a potential candidate risk factor
for the development of gastric cancer [33, 34]. However, Yuan
et al. suggested that the OGG1 326Cys allele plays a
significant protective effect to breast cancer in European
women and Duan et al. established solid statistical evidence
for an association between the OGG1 Cys/Cys genotype and
lung cancer risk [35, 36]. This phenomenon indicates that the
OGG1 Ser326Cys polymorphism exerts different effect on
various types of cancers. So, it is necessary for us to get a
better understanding of OGG1 Ser326Cys polymorphism on
PC susceptibility, especially when inclusive and controversial
findings still exist. In our present meta-analysis, OGG1
Ser326Cys polymorphism was not significantly associated
with PC risk. Subgroup analysis was based on ethnicity,
source of control, sample size, and genotyping method; we
could not achieve a significant association between OGG1
Ser326Cys polymorphism and PC susceptibility.
When performing meta-analysis, testing the heterogeneity
among studies is very important. In the current study,
significant heterogeneity was only found in the dominant
model. Then, we did subgroup analysis to search the source
of heterogeneity. Interestingly, it seems that the ethnicity is not
the source of heterogeneity, suggesting that OGG1
Ser326Cys polymorphism may not have race-specific effects
on PC susceptibility. We found that the source of control and
sample size may contribute substantial heterogeneity. It is
possible that some limitations of recruited studies may
partially contribute to the observed heterogeneity. For this
reason, we conducted analyses using the random effects
model. In addition, publication bias is another aspect which
may make a negative effect on our meta-analysis. Both funnel
plot and Egger’s test were applied to test the publication bias.
Our results suggest that the publication bias have little effect
on the results of our study, and the results of our meta-analysis
are relatively stable.
Although comprehensive analysis was conducted to explore
the association between OGG1 Ser326Cys polymorphism and
PC susceptibility, there are still some limitations. Firstly, the
primary studies mainly provided data towards Caucasians;
therefore, other ethnicities should be researched in future studies.
Secondly, only three studies used controls that were population-
based. Other articles used hospital-based controls, whichmay not
be representative of the general population. Thirdly, the number
of samples included in the meta-analysis was relatively small.
In spite of the shortages above, our meta-analysis also had
several advantages. Firstly, strict searching strategy which
combines computer-assisted with manual search makes the
eligible studies included as much as possible. Secondly, the
quality of case–control studies met our inclusion criteria and
was satisfactory, and the sensitivity analysis and publication
bias analysis indicated the stability and credibility of the meta-
analysis, which leads to a more convincing result. More
importantly, the process of literature selection, data extraction,
and data analysis were well designed and conducted.
In conclusion, this is the first meta-analysis evaluating the
association between OGG1 Ser326Cys polymorphism and PC
susceptibility. The pooled results suggest that the OGG1
Ser326Cys polymorphism may not be associated with PC
susceptibility. Considering the limited sample size and
ethnicities included in the meta-analysis, further larger-scaled
and well-designed studies are needed to confirm our results.
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